These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33115264)

  • 1. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma.
    Liu G; Wang Y; Wang C; He Y; E M
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1423-1430. PubMed ID: 33115264
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
    Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
    [No Abstract]   [Full Text] [Related]  

  • 4. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
    Hu L; Kong Z; Meng Q; Wang J; Zhou M; Yu J; Jiang X
    Med Sci Monit; 2020 Nov; 26():e927221. PubMed ID: 33243967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
    Chu L; Chen Y; Liu Q; Liang F; Wang S; Liu Q; Yu H; Wu X; Zhang J; Deng J; Ai D; Zhu Z; Nie Y; Zhao K
    Oncologist; 2021 Jun; 26(6):e925-e935. PubMed ID: 33393167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
    Chi D; Chen B; Guo S; Bai K; Ma H; Hu Y; Li Q; Zhu Y
    Aging (Albany NY); 2021 Mar; 13(6):8408-8420. PubMed ID: 33713398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhao J; He M; Li J; Li D; Zhao Y; Li X; Zhang X; Chen X; Liu Y; Zhao L
    Cancer Biother Radiopharm; 2022 May; 37(4):324-331. PubMed ID: 34524004
    [No Abstract]   [Full Text] [Related]  

  • 8. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
    Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
    Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
    Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
    Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
    Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
    [No Abstract]   [Full Text] [Related]  

  • 11. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
    Liu Z; Ou W; Li N; Wang SY
    Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
    Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
    Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma].
    Qi L; Zhang B; Liu Y; Mu L; Li Q; Wang X; Xu JP; Wang XY; Huang J
    Zhonghua Zhong Liu Za Zhi; 2023 Mar; 45(3):259-264. PubMed ID: 36944547
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients.
    Su R; Zhu J; Wu S; Luo H; He Y
    Technol Cancer Res Treat; 2022; 21():15330338211072974. PubMed ID: 35072577
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
    Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375).
    Wei J; Su J; Wang J; Jia X; Zhao Q; Shi W; Wang H; Zheng Z; Jiang X
    Head Neck; 2024 Apr; 46(4):915-925. PubMed ID: 38220218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of apatinib for the treatment of gastric cancer.
    Geng R; Song L; Li J; Zhao L
    Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
    Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
    Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy and safety of apatinib in advanced squamous cell carcinoma of the lung.
    Li X; Le L; Han L; Zhang Y; Sun S
    Indian J Cancer; 2017; 54(3):547-549. PubMed ID: 29798956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.